20 articles for PC Tyler
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Tight binding enantiomers of pre-clinical drug candidates.
Victoria University of Wellington
Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
Industrial Research
Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics.
Industrial Research
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.
Industrial Research
Immucillins in custom catalytic-site cavities.
Albert Einstein College of Medicine of Yeshiva University
Second generation transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase.
Industrial Research
Targeting the polyamine pathway with transition-state analogue inhibitors of 5'-methylthioadenosine phosphorylase.
Industrial Research
Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase.
Industrial Research
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
Industrial Research
Design and synthesis of potent"sulfur-free" transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-methylthioadenosine phosphorylase.
Industrial Research
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
Industrial Research
Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase.
Albert Einstein College of Medicine
Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Johnson & Johnson Pharmaceutical Research & Development
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.
Aventis Pharma Deutschland